Drew H. Barzman, MD
Director, Child and Adolescent Forensic Psychiatry Service
and his child forensic research team developed the Brief Rating of Aggression by Children and Adolescents (BRACHA), a reliable instrument for predicting aggression and violence in the hospital. His team has also studied salivary biomarkers associated with future aggression by children. Currently, his team is combining fMRI, salivary biomarkers and the BRACHA to better predict pediatric aggression and violence. In addition, his child forensic team has developed one the largest databases on pediatric aggression and violence for analysis.
513-636-8727
drew.barzman@cchmc.org
Drew H. Barzman, MD
Director, Child and Adolescent Forensic Psychiatry Service
Academic Information
Assistant Professor, Division of Pediatric Psychiatry
Show All
Specialties
Clinical InterestsChild and adolescent forensic psychiatry Research InterestsChild and adolescent forensic psychiatry; prevention of violence in youth; neuroimaging in children and adolescents; genetics; pediatric clinical trials
Biography
Dr. Barzman’s most significant professional achievements include helping children and families, research, and mentoring undergraduate and graduate students.
Education and Training
MD: Buffalo, School of Medicine, State University of New York, 1997. Residency: Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, 1997-2001. Fellowship: Forensic Fellow, Department of Psychiatry, University of Cincinnati, Cincinnati, OH, 2001-2002. Fellowship: Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, 2002-2004. Licensure: State of Ohio Medical License, 2001. Certifications: Psychiatry (2002), Forensic Psychiatry (2003), Child and Adolescent Psychiatry (2004); Dr. Barzman successfully passed the Maintenance of Certification Examination in Psychiatry, Forensic Psychiatry, and Child and Adolescent Psychiatry in April 2011. Recertification: Passed Modular Examination for Maintenance of Certification in the Specialty of Psychiatry and the Subspecialties of Forensic Psychiatry and Child and Adolescent Psychiatry in April 2011.
Publications
View PubMed Publications
Barzman D, Mossman D, Appel K, Blom T, Strawn J, Ekhator N, Patel B, DelBello M, Sorter M, Klein D, Geracioti T. The Association Between Salivary Hormone Levels and Children’s Inpatient Aggression: A Pilot Study. Psychiatric Quarterly. Epub ahead of print. 2013. Barzman D, Mossman D, Sonnier L, Sorter M. Brief Rating of Aggression by Children and Adolescents (BRACHA): A Reliability Study. Journal of the American Academy of Psychiatry and the Law. 2012;40(3):374-382. Barzman D, Brackenbury L, Sonnier L, Schnell B, Cassedy A, Salisbury S, Sorter M, Mossman D. Brief Rating of Aggression by Children and Adolescents (BRACHA): Development of a Tool to Assess Risk of Inpatients’ Aggressive Behavior. Journal of the American Academy of Psychiatry and the Law. 2011;39(2):170-179. Barzman D, Patel A, Sonnier L, Strawn J. Neuroendocrine Aspects of Pediatric Aggression: Can Hormone Measures Be Clinically Useful? Neuropsychiatric Disease and Treatment. 2010;6:691-697. Brackenbury L, Barzman D, Dunseith Neal. Evaluating Forensic Interviewing of Children in Sexual Abuse Cases: Guidelines for the Forensic Psychiatrist. American Journal of Forensic Psychiatry. 2009;30 (2). Barzman DH, Findling RL. Pharmacological treatment of pathologic aggression in children. Int Rev Psychiatry. 2008 Apr;20(2):151-7. Barzman DH, Delbello MP, Fleck DE, Lehmkuhl H, Strakowski SM. Rates, types, and psychosocial correlates of legal charges in adolescents with newly diagnosed bipolar disorder. Bipolar Disorders. 2007;9(4):339-44. Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM. The Efficacy and Tolerability of Quetiapine versus Divalproex for the Treatment of Impulsivity and Reactive Aggression in Adolescents with Co-occurring Bipolar Disorder and Disruptive Behavior Disorder(s). The Journal of Child and Adolescent Psychopharmacology. 2006;16(6):665-70. DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA., Barzman DH, Nelson E, Strakowski SM. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:305-313. Barzman DH, DelBello MP, Kowatch RA, Gernert B, Fleck DE, Pathak S, Rappaport K, Delgado SV, Pamela Campbell, Strakowski SM. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. The Journal of Child and Adolescent Psychopharmacology. 2004;14:593-600.
Grants
Identification of Genetic Predispositions for Bipolar Disorder in Children. Co-Principal Investigator. Oxley Foundation. Dec 2011 - Nov 2014. Uncovering the Neural Circuitry of Pediatric Aggression. Principal Investigator. Center for Clinical and Translational Science and Training (CCTST) (University of Cincinnati Academic Health Center). Sep 2012 - Jun 2013. Bipolar Disorder Imaging & Treatment Research Center. Co-Investigator. NIMH. Jul 2007 - Jun 2013. P50 MH077138.
|
Sergio V. Delgado, MD
Medical Director of Outpatient Services, Division of Child and Adolescent Psychiatry
is a clinical investigator who has clinical trial research programs in depression in the Division of Psychiatry.
513-636-4788
sergio.delgado@cchmc.org
Sergio V. Delgado, MD
Medical Director of Outpatient Services, Division of Child and Adolescent Psychiatry
Chair, Child Psychoanalytic Program
Academic Information
Professor, Division of Pediatric Psychiatry
Show All
Specialties
Learning disorders; ADHD; psychotherapy
Biography
Dr. Delgado is a professor in the Division of Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati. He is the medical director of Outpatient Services and director of Psychotherapy Services in the Division of Psychiatry at Cincinnati Children’s Hospital Medical Center. His research involves the pharmacological treatment of children and adolescents with ADHD, bipolar disorders and depression. He also is a supervising and training adult and child analyst at the Cincinnati Psychoanalytic Institute.
Education and Training
MD: Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 1981. Residency: Karl Menninger School of Psychiatry, Topeka, KS. Fellowship: Child and Adolescent Psychiatry, Karl Menninger School of Psychiatry, Topeka, KS. Certifications: Psychiatry, 1988; Child and Adolescent Psychiatry, 1990; Psychoanalysis, 1994; Child and Adolescent Psychoanalysis, 1994.
Publications
View PubMed Publications
Delgado SV, Strawn J. Termination of psychodynamic psychotherapy with adolescents: a review and contemporary perspective. Bulletin of the Menninger Clinic. 2012;76(1):21-52. Delgado SV, Wassenaar E, Strawn J. Psychiatric disorder or nonverbal learning disorder? Current Psychiatry. 2011;10(5):17-34. Kowatch RA, Monroe E, Delgado SV. Not all mood swings are bipolar disorder. Current Psychiatry. 2011;10(2):39-52. Harris E, Eng HY, Kowatch R, Delgado SV, Saldana SN. Disinhibition as a Side Effect of Treatment with Fluvoxamine in Pediatric Patients with Obsessive Compulsive Disorder. J Child Adolesc Psychopharmacol. 2010. DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11:483–493. Delgado, SV. Psychotherapy Rounds. Psychodynamic Psychotherapy for Children and Adolescents: An Old Friend Revisited. Psychiatry. 2008;5(5):67-72.
|
Craig A. Erickson, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Fragile X syndrome; autism spectrum disorders
Education and Training
MD: University of Cincinnati Residency: Psychiatry, Indiana University; Child and Adolescent Psychiatry, Indiana University.
Publications
View PubMed Publications
Erickson CA, Mullett JE, McDougle CJ. Brief Report: Acamprosate in fragile X syndrome. J Autism Dev Disorder, 2010 Mar 6. Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Current Treat Options Neurology. 12: 529-538, 2010. Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol. Feb;20(1):75-8, 2010. Wink LK, Erickson CA, Chambers JE, McDougle CJ. Comorbid intellectual disability and borderline personality disorder: A case series. Psychiatry. 73(3): 279-289, 2010. Erickson CA, Stigler KA, Wink LK, Weng N, Weiler IJ, Greenough WT, McDougle CJ. Riluzole in Fragile X Syndrome, Brain Research, 1380: 264-70, 2011. Erickson CA, Early M, Wink LK, McDougle CJ. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder, Journal of Child Adolesc Psychopharmacology, 2012. Wink LK, Erickson CA, Stigler KA, McDougle CJ. Riluzole in autistic disorder, Journal of Child and Adolescent Psychopharmacology. 2012. Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, McDougle CJ. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology. 2011 Feb 12. Kowalski JL, Wink LK, Blankenship K, Habenicht CD, Erickson CA, Stigler KA, McDougle CJ. Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacology. 2012.
Grants
A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders. Principal Investigator. Department of Defense. Mar 2010-Feb 2014. W81XWH-09-10091. Extracellular Signal-Related Kinase Biomarker Development in Autistic Disorder. Principal Investigator. Simons Research Foundation. Sep 2012-Aug 2014. Autism Speaks Treatment Award. Principal Investigator. Autism Speaks. Jan 2013-Dec2015.
|
Elana Harris, MD, PhD
is a child and adolescent psychiatrist and neuroscientist. Her basic and translational research programs study the function of the brain areas involved in obsessive compulsive disorder and Tourette syndrome. Her lab uses magnetoencephalography, transcranial magnetic stimulation and functional MRI to learn more about the pathophysiology of these disorders.
513-803-0670
elana.harris@cchmc.org
Elana Harris, MD, PhD
Academic Information
Assistant Professor, Other
Show All
Specialties
Anxiety disorders; Obsessive Compulsive Disorder, Tourette Syndrome
Cognitive neuroscience; neurophysiology as a tool to improve our understanding of the etiology and pathophysiology of mental illness; improving treatment of anxiety disorders and Tourette Syndrome using cognitive behavior therapy, biofeedback and habit reversal therapy
Education and Training
MD: State University of New York, Downstate Medical Center
PhD: Neural and Behavioral Science; State University of New York, Downstate Medical Center
Internship: Pediatrics, Winthrop University Hospital, Mineola, NY
Residency: Psychiatry, Johns Hopkins Hospital, Baltimore, MD
Fellowship: Child and Adolescent Psychiatry, Johns Hopkins Hospital, Baltimore, MD
Publications
Harris, E., Witter, M. P., Weinstein, G., and Stewart, M. Intrinsic connectivity of the rat subiculum. I. Dendritic morphology and patterns of axonal arborization by pyramidal neurons. J. Comp. Neurol., 2001; 436:490-505. Harris, E. and Stewart, M. Intrinsic connectivity of the rat subiculum. II. Properties of synchronous spontaneous activity and a demonstration of multiple generator regions. J. Comp. Neurol., 2001; 436:506-518. Harris, E. and Stewart, M. Propagation of synchronous epileptiform events from subiculum backward into area CA1 of rat brain slices. Brain Res., 2001, 895: 41-49. Presentations, Most RecentHarris, E. Brain structures underlying fear. Presented to the Child Psychiatry Residency Training Program at CCHMC. February 2, 2008; Cincinnati, OH. Harris, E.; Gilbert, D. The premotor potential in simple vs. complex motor tics. Presented at the MEG Users' Meeting. November 8, 2007; Cincinnati, OH.
|
Brian P. Kurtz, MD
Attending Psychiatrist, Division of Child and Adolescent Psychiatry
is the Director of the Psychiatry Consultation-Liaison Service at CCHMC. Prior to joining the faculty in 2011, he was the Director of the Pediatric Consultation-Liaison Psychiatry Program at Tufts Medical Center in Boston, MA.
513-636-4788
brian.kurtz@cchmc.org
Brian P. Kurtz, MD
Attending Psychiatrist, Division of Child and Adolescent Psychiatry
Academic Information
Assistant Professor, Division of Pediatric Psychiatry
Show All
Specialties
Consultation-liaison psychiatry; psychiatry with medical comorbidity
Education and Training
MD: The Ohio State University, Columbus, OH, 2004. Internship: Pediatrics, Children’s National Medical Center, Washington, DC, 2005. Residency: Psychiatry, The Cambridge Hospital, Cambridge, MA, 2008. Fellowship: Child and Adolescent Psychiatry, Massachusetts General Hospital/McLean Hospital, Boston, MA, 2010. Certification: Psychiatry, 2008; Child and Adolescent Psychiatry, 2010.
Publications
Kurtz BP, Abrams AN. Psychiatric aspects of pediatric oncology. Pediatr Clin N Am. 2011 Aug;58(4):1003-1023. Kurtz BP, Abrams AN. Psychiatric aspects of pediatric oncology. Child Adolesc Psychiatr Clin N Am. 2010 Apr;19(2):401-421.
|
Logan K. Wink, MD
is an assistant professor of Clinical Psychiatry who specializes in Autism Spectrum Disorders and related developmental disabilities. Her clinical research include descriptive studies and drug trials in Angelman syndrome and Autism Spectrum Disorders.
513-636-4611
logan.wink@cchmc.org
Logan K. Wink, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Autism spectrum disorders; Angelman syndrome
Biography
Dr. Logan Wink is an assistant professor of Clinical Psychiatry at Cincinnati Children’s Hospital Medical Center. Dr. Wink is a child and adolescent psychiatrist involved in clinical research and clinical care of individuals with developmental disabilities, including Autism Spectrum Disorders and Angelman Syndrome. Her primary research focus is improving clinical care of individuals with developmental disabilities through better understanding the pathology of these disorders and improving pharmacologic treatment.
Education and Training
MD: Indiana University School of Medicine, Indianapolis, IN. Residency: Psychiatry, Indiana University School of Medicine, Indianapolis, IN. Fellowship: Child Psychiatry, Indiana University School of Medicine, Indianapolis, IN. Fellowship: Autism and Developmental Disabilities, Indiana University School of Medicine, Indianapolis, IN.
Publications
View PubMed Publications.
Erickson CA, Wink LK, Schaefer TL, Shaffer RC. Medication Management of Fragile X Syndrome. In The Comprehensive Guide to Autism, Patel VP, Preedy VR, Martin CR (eds), Springer Reference, Heidelberg, Germany. 2013. Wink LK, Erickson CA, McDougle CJ, Stigler KA. Pharmacotherapy of autism spectrum disorders. In The Handbook of Autism: A Concise Guide, Treadwell-Deering D, Kober D (eds), World Scientific, Inc., New Jersey, 2013. Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ. An Open-Label Naturalistic Pilot Study of Acamprosate in Youth with Autistic Disorder. J Child Adolesc Psychopharmacol. 2011 Dec 2. Wink LK, Erickson CA, Stigler, KA, McDougle CJ. Riluzole in autistic disorder. J Child Adolesc Psychopharmacology. 2011;21(4):375-379. Kowalski JL, Wink LK, Blankenship K, Habenicht CD, Erickson CA, Stigler KA, McDougle CJ. Paliperidone Palmitate in a Child with Autistic Disorder. J Child Adolesc Psychopharmacology. 2011 Oct;21(5):491-3. Orsagh-Yentis DK, Wink LK, Erickson CA, Stigler KA, McDougle CJ. Buspirone for Bruxism in a Child with Pervasive Developmental Disorder-Not Otherwise Specified. J Child Adolesc Psychopharmacol. 2011 Dec. Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ. An Open-Label Naturalistic Pilot Study of Acamprosate in Youth with Autistic Disorder. J Child Adolesc Psychopharmacol. 2011 Dec. Wink LK, Plawecki MH, Erickson CA, Stigler KA, McDougle CJ. Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. Expert Opin Emerg Drugs. 2010 May. Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Current Treat Options Neurology. 2010;12: 529-538. Wink LK, Erickson CA, Chambers JE, McDougle CJ: Comorbid intellectual disability and borderline personality disorder: A case series. Psychiatry. 2010;73(3):279-289.
Grants
Characterization of Angelman Syndrome. Site Investigator. National Institutes of Health. Jan 2006 - Jun 2016. A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders. Co-Investigator. Department of Defense. Mar 2010 - Feb 2014. A Trial of Levodopa in Angelman Syndrome. Site Investigator. United States Food and Drug Administration Office of Orphan Products Development. Jul 2010 - Jun 2014. Extracellular Signal-Related Kinase Biomarker Development in Autistic Disorder. Co-Investigator. Simons Research Foundation SFARI PILOT AWARD. Sep 2012 - Aug 2014. A randomized, double blind, placebo-controlled crossover study to evaluate riluzole for treatment of drug-refractory irritability in autism spectrum disorder. Primary Investigator. Pilot Research Award, Center for Clinical and Translational Science and Training. University of Cincinnati Academic Health Center. Jul 2013 - Jun 2014. Acamprosate in Autistic Disorder. Co-Investigator. Autism Speaks. Jan 2013 - Dec 2015. Acamprosate in Fragile X Syndrome. Co-Investigator. John Merck Fund Translational Research Program Award. Jan 2013 - Dec 2016. FRAGILE X CLINICAL AND RESEARCH CONSORTIUM FORWARD REGISTRY AND DATABASE. Co-Investigator. National Fragile X Foundation/Centers for Disease Control. Sep 2012 - Dec 2014. A Double Blind, Placebo-Controlled Phase III trial of evaluating the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Fragile X Syndrome in youth. Co-Investigator. Seaside Therapeutics. Oct 2012 - Oct 2013. A Double Blind, Placebo-Controlled Phase II trial of evaluating the Efficacy, Safety, and Tolerability of RO4917523 in the Treatment of Fragile X Syndrome in adolescents and adults. Co-Investigator. F. Hoffmann LaRoche. Sep 2012 - Sep 2013. AUTISM SPECTRUM DISORDER GENE EXPRESSION ANALYSIS (STORY) STUDY. Primary Investigator. SynapDx. CCHMC Site.
|
